New
Tirzepatide
181,50 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 22.5% in SURMOUNT-1.
- A 2.0–2.3% reduction in HbA1c in the SURPASS program.
- Superior glycemic control compared with semaglutide in a direct comparative trial.
- Reduction in triglycerides and LDL.
- Improvement in sleep apnea in the SURMOUNT-OSA trial.
- Approved by the FDA for T2DM as Mounjaro and for obesity as Zepbound.
Description
Tirzepatide
Diabetes / Weight Loss
MECHANISM OF ACTION
Dual GIP/GLP-1 receptor coagonist, with a GIP-based mechanism. Activation of the GIPR potentiates insulin, suppresses glucagon, promotes direct lipolysis in adipocytes, and modulates the central nervous system. GLP-1R promotes satiety, delays gastric emptying, and stimulates glucose-dependent insulin secretion. The C20 diacid fatty acid chain extends the half-life to approximately 5 days with weekly administration.
KEY BENEFITS
- Body weight reduction of up to 22.5% in SURMOUNT-1.
- A 2.0–2.3% reduction in HbA1c in the SURPASS program.
- Superior glycemic control compared with semaglutide in a direct comparative trial.
- Reduction in triglycerides and LDL.
- Improvement in sleep apnea in the SURMOUNT-OSA trial.
- Approved by the FDA for T2DM as Mounjaro and for obesity as Zepbound.
SIDE EFFECTS AND SAFETY
Gastrointestinal effects such as nausea, vomiting, and diarrhea. Class warning regarding C-cell thyroid tumors. Risk of pancreatitis. Dose titration is essential. Monitor renal function if gastrointestinal effects occur.
RESEARCH AND CLINICAL NOTES
SURPASS-2, a head-to-head trial against semaglutide: tirzepatide was superior in both HbA1c and body weight. SURMOUNT-1: 22.5% reduction in body weight. Dual-action peptide approved by the FDA for dual indications, marketed as Mounjaro and Zepbound. Second-largest commercial impact after semaglutide.
TARGET PROFILE:
Metabolic medicine, endocrinology, bariatric medicine, and weight loss.
Additional information
| Weight | ,26 kg |
|---|
You may also like…
Hot
Algal Oil Omega 3 EPA/DHA, 100 capsules
- Vegan source of Omega-3: Schizochytrium microalgae oil, a sustainable alternative to fish oil.
- Cardiovascular health: DHA and EPA help reduce triglycerides, improve circulation, and control blood pressure.
- Brain and cognitive wellness: Supports memory, concentration, and prevents cognitive decline.
- Eye health: DHA is an essential component of the retina, helping maintain optimal vision.
- Anti-inflammatory properties: Alleviates symptoms of arthritis and other chronic inflammatory diseases.
- Suitable for vegans: Free from gluten, lactose, and preservatives.
Related products
5-Amino-1MQ
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Accelerated lipolysis and fat oxidation without thermogenic effects.
- Improved mitochondrial efficiency and ATP production.
- Supports insulin sensitivity and glucose homeostasis.
- Interest in body recomposition protocols in combination with GLP-1 agonists.
- Supports NAD+ levels relevant to cellular longevity.
New
CJC-1295 5 mg without DAC + IPA 5 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Synergistic optimization of endogenous GH secretion.
- Reference GH Peptide Stack for Body Composition.
- Increased lean body mass, fat loss, and recovery.
- Maintenance of the pulsatile rhythm of GH, with lower long-term risk.
- Ipamorelin's selectivity minimizes the increase in cortisol and prolactin.
CJC-1295 without DAC
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Physiological pattern of pulsatile GH secretion.
- Lower risk of desensitization compared to the DAC version.
- Improved body composition and recovery.
- Improved sleep quality, with synergistic effects when taken at night.
- Suitable for use in combination with GHRP-class peptides.
New
DSIP
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved sleep quality, especially deep, slow-wave (delta) sleep.
- Stress-reducing and anxiolytic effects.
- Normalization of disrupted sleep patterns.
- Potential application in opioid/alcohol withdrawal syndrome.
- Geroprotector: Anticancer Properties in Animal Models.
MOTS-c
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- AMPK-mediated metabolic improvements, including glucose and fat utilization.
- Mimetic properties of exercise.
- Anti-inflammatory and anti-aging effects.
- Supports bone metabolism through osteoblastic activity.
- Protection against age-related physical decline.
- Potential for research on T2DM and obesity management.
New
PT-141
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved sexual desire in men and women.
- Improvement of erectile function via the central nervous system.
- Approved by the FDA for HSDD in premenopausal women as Vyleesi.
- Effective in patients who do not respond to PDE5 inhibitors.
- It can be used as needed, 45–90 minutes before the activity.
New
Selank
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Rapid anxiolytic effect without sedation or dependence.
- Cognitive improvement: memory consolidation and processing speed.
- Mood stabilization and resilience to stress.
- Modulation of the immune system through tuftsin activity.
- Minimal side effects compared to benzodiazepines.
- Used clinically in Russia to treat anxiety and cognitive disorders.
New
TB500
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Systemic repair and regeneration of soft tissues.
- Accelerated wound healing and scar reduction.
- Improved tissue flexibility and reduced inflammation.
- Cardiac protection and myocardial repair.
- Eye repair in research on corneal regeneration.
- Protection of renal podocytes.
